Companies /Healthcare

Invivyd Inc

NASDAQ: IVVD Biotechnology
$0.41
▼ $0.03 (−7.45%) today
Markets closed · 2:12pm ET

IVVD at a Glance

Valuation
Market cap
$122.0M
Profitability
Revenue (TTM)
$60.7M
Profit margin
-214.8%
EPS (TTM)
$-0.38
Price
52-week range
$0 – $3
Street target
$10.00

Headquartered in New Haven, CT Fiscal year ends December NASDAQ: IVVD invivyd.com

About Invivyd

Invivyd, Inc. (Nasdaq: IVVD) is a commercial-stage biopharmaceutical company developing monoclonal antibodies (mAbs) for protection against serious viral infectious diseases, starting with SARS-CoV-2. It uses a proprietary integrated technology platform to assess, monitor, develop and adapt antibodies as viruses evolve.

**Commercial product:** PEMGARDA (pemivibart) is a half-life extended mAb authorized by the U.S. FDA under an Emergency Use Authorization since March 2024. It is used for pre-exposure prophylaxis of COVID-19 in moderately-to-severely immunocompromised adults and adolescents and is sold through an in-house sales force. HHS has announced that the underlying emergency declaration terminates June 29, 2027.

**Lead candidate:** VYD2311 (ibramvibart) is an intramuscular-capable mAb built on the same antibody backbone as pemivibart. It is being studied in the REVOLUTION program:
- DECLARATION, a Phase 3 prevention trial of about 2,400 participants intended to support a BLA under the FDA Accelerated Approval Program;
- LIBERTY, a Phase 3 safety and co-administration study versus an mRNA vaccine;
- FLINTLOCK, a Phase 2 trial in Long COVID and COVID vaccine injury, conducted with the SPEAR Study Group.

**Measles:** VMS063 is a preclinical measles Fusion-protein mAb candidate for treatment and prevention, targeted for clinical development in 2027. Updated

IVVD Coverage

Frequently Asked Questions

What does Invivyd do?

Invivyd, Inc. (Nasdaq: IVVD) is a commercial-stage biopharmaceutical company developing monoclonal antibodies (mAbs) for protection against serious viral infectious diseases, starting with SARS-CoV-2.

What is the IVVD stock price target?

The Wall Street consensus 12-month price target for IVVD is $10.00.